SanBio Co (4592) AI Stock Analysis

• Market Cap: ¥176.20B
• Dividend Yield: N/A
• Average Volume (3M): 2.08M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.10
• Revenue Growth: N/A
• EPS Growth: -12.69%
• Country: JP
• Employees: 29
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -9.95
• Shares Outstanding: 78,033,330
• 10 Day Avg. Volume: 2,869,570
• 30 Day Avg. Volume: 2,080,090
• PEG Ratio: -5.05
• Price to Book (P/B): 28.13
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -13.74
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: ¥2,050.00
• Price Target Upside: -8.07% Downside
• Rating Consensus: Hold
• Number of Analyst Covering: 2
• EPS Forecast (FY): -24.53
• Revenue Forecast (FY): ¥3.58B

• Rating: 48 Neutral
• Price Target: ¥2,233.00 ▲(0.13% Upside)
• Action: Reiterated Date: 02/18/26
• Date: Action: Reiterated 02/18/26

The score is held down primarily by weak financial performance (minimal revenue, large ongoing losses, and persistent cash burn) and a valuation profile dominated by losses (negative P/E, no dividend). Technicals provide some support due to strong recent momentum, though near-overbought readings add caution.

Positive Factors

Proprietary cell therapy platform

SanBio's proprietary cell-therapy platform targeting CNS disorders creates a durable R&D foundation. A platform approach can support multiple indications and licensing opportunities, providing long-term strategic optionality and higher barriers to entry if clinical efficacy is demonstrated.

Lower leverage and reduced debt

Material reduction in total debt and only moderate leverage reduce refinancing pressure and interest burden, improving financial flexibility. Over months this gives management more options to fund trials, pursue partnerships, or time financing more favorably, lowering short-term solvency risk.

Lean R&D organization

A 29-person team implies a focused, low-overhead operating model that can extend cash runway and speed decision-making. For a development-stage biotech, a compact organization can concentrate expertise, control fixed costs, and preserve capital while advancing key clinical milestones.

Negative Factors

No commercial revenue

The absence of reported revenue implies no internal cash generation and a reliance on external financing to sustain operations. Structurally, this elevates execution and financing risk over months, as successful transition to commercial income is required for durable self-sufficiency.

Persistent cash burn

Consistent negative operating and free cash flows indicate the business consumes cash roughly in line with accounting losses. This structural burn creates ongoing funding dependence, raising the likelihood of dilution or strained financing conditions unless burn meaningfully improves or partnerships materialize.

Eroding equity and negative returns

Sharp equity erosion and deeply negative ROE reflect cumulative losses that weaken the balance sheet and reduce strategic flexibility. Over time this increases vulnerability to adverse trial outcomes, raises refinancing costs, and heightens dilution risk when new capital is required.

SanBio Co Business Overview & Revenue Model

Company Description

SanBio Company Limited develops, produces, and sells regenerative cell medicines for the central nervous system. The company develops SB623 that has completed a phase 2 clinical trial to treat traumatic brain injury in the United States and Japan. Its research pipeline products also comprise SB623 for ischemic and hemorrhagic strokes, age-related macular degeneration, retinitis pigments, spinal cord injury, Parkinson's disease, Alzheimer's disease, and others; SB618 for peripheral nerve damage; SB308 for muscular dystrophy disease; MSC1 for cancer; and MSC2 for inflammatory disease and optic neuritis. The company was founded in 2001 and is headquartered in Tokyo, Japan.

How the Company Makes Money

SanBio Co. generates revenue through the development and commercialization of its cell therapy products, primarily targeting neurological conditions. The company's revenue model includes product sales, licensing agreements, and strategic partnerships with other pharmaceutical and biotechnology companies. Key revenue streams are anticipated from successful clinical trials leading to market approval and subsequent commercialization of their proprietary therapies. SanBio also collaborates with research institutions and industry partners to enhance its research and development capabilities, which can lead to milestone payments and royalties once products reach the market.

SanBio Co Financial Statement Overview

Summary

Income and cash flow quality are weak: revenue is essentially zero in recent years while large losses persist, and operating/free cash flow remain materially negative (ongoing cash burn and funding dependence). The balance sheet is a relative positive with moderate leverage and reduced debt, but shrinking equity and deeply negative returns reflect continued erosion risk.

Income Statement

Revenue is essentially absent in the most recent years (annual reports show total revenue at 0 from 2021–2025), while losses remain very large. Profitability is deeply negative with EBIT and net income consistently in the billions of yen in the red, although the net loss narrowed in 2024–2025 versus 2023. Overall, the income profile reflects a company still in heavy investment mode with limited commercial traction and weak earnings visibility.

Balance Sheet

Leverage looks moderate in recent years (debt-to-equity around ~0.23 in 2023–2025) and total debt has come down materially from earlier periods, which is a positive. However, equity has also declined sharply over time, and returns to shareholders are strongly negative (return on equity is deeply below zero), consistent with ongoing losses and balance-sheet erosion risk if losses persist.

Cash Flow

Cash burn is substantial and persistent: operating cash flow and free cash flow are negative every year shown, with only partial improvement in 2024–2025 versus 2023. Free cash flow broadly tracks net losses (free cash flow to net income near ~1), indicating limited non-cash addbacks and a business that is consuming cash roughly in line with accounting losses. This raises funding dependence and refinancing/issuance risk unless the burn rate continues to improve.

Breakdown	TTM	Jan 2025	Jan 2025	Jan 2024	Jan 2023	Jan 2022
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00	0.00
Gross Profit	-8.26M	-9.37M	-14.50M	-24.61M	-132.47M	-74.45M
EBITDA	-4.40B	-3.51B	-4.53B	-4.62B	-4.37B	-5.73B
Net Income	-3.57B	-2.88B	-2.64B	-5.56B	-4.68B	-3.39B
Balance Sheet
Total Assets	3.22B	3.45B	5.05B	7.05B	5.51B	13.34B
Cash, Cash Equivalents and Short-Term Investments	2.74B	2.92B	4.45B	6.73B	4.56B	12.48B
Total Debt	1.36B	397.00M	665.00M	933.00M	2.52B	4.00B
Total Liabilities	1.93B	1.68B	2.25B	2.62B	3.48B	4.99B
Stockholders Equity	1.29B	1.76B	2.79B	4.43B	2.04B	8.35B
Cash Flow
Free Cash Flow	0.00	-3.61B	-4.82B	-7.44B	-6.60B	-5.35B
Operating Cash Flow	0.00	-3.62B	-4.78B	-7.43B	-6.55B	-5.22B
Investing Cash Flow	0.00	-4.27M	-19.03M	-10.10M	-66.26M	4.18B
Financing Cash Flow	0.00	2.09B	2.38B	9.45B	-1.50B	-56.57M

SanBio Co Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 2230.00
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4592, the sentiment is Positive. The current price of 2230 is above the 20-day moving average (MA) of 2087.90, above the 50-day MA of 1894.32, and below the 200-day MA of 2422.61, indicating a neutral trend. The MACD of 92.82 indicates Negative momentum. The RSI at 59.88 is Neutral, neither overbought nor oversold. The STOCH value of 38.89 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:4592.

SanBio Co Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
4978	59 Neutral	¥17.82B	-54.84	―	―	1.24%	-33.41%
7774	54 Neutral	¥32.33B	-70.05	―	―	-5.65%	-469.19%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
4593	50 Neutral	¥59.40B	-18.92	―	―	-82.33%	47.73%
7776	49 Neutral	¥14.17B	-11.63	―	―	-42.49%	-2.37%
4592	48 Neutral	¥176.20B	-46.79	-636.97%	―	―	-12.69%
4599	43 Neutral	¥19.24B	-10.06	―	―	―	11.34%

SanBio Co Corporate Events

SanBio Finalizes Employee Stock Option Terms for 75,000 Shares

SanBio has finalized the terms for a new stock option program, approving the issuance of 75,000 share acquisition rights tied to an equal number of common shares at an exercise price of 1,898 yen per share. All of the options will be granted to three employees, underscoring the company’s use of equity-based compensation to align key staff with shareholder interests and support talent retention during its growth phase in the competitive biotech market.

The most recent analyst rating on (JP:4592) stock is a Sell with a Yen1815.00 price target. To see the full list of analyst forecasts on SanBio Co stock, see the JP:4592 Stock Forecast page.

SanBio Issues New Employee Stock Options to Support Long-Term Growth

SanBio has approved the issuance of its 36th series of share acquisition rights as part of its stock option program, granting up to 75,000 stock options linked to an equal number of common shares to three employees. The program is designed to strengthen employee motivation, support the recruitment and retention of key talent, and align staff incentives with the company’s medium- to long-term performance, thereby reinforcing corporate value and shareholder interests through equity-based compensation.

The most recent analyst rating on (JP:4592) stock is a Hold with a Yen1651.00 price target. To see the full list of analyst forecasts on SanBio Co stock, see the JP:4592 Stock Forecast page.

SanBio Co. Records Significant Non-Operating Expenses and Deferred Income Taxes

SanBio Co., Ltd. announced the recording of significant non-operating expenses and deferred income taxes in the third quarter of the fiscal year ending January 31, 2026. The company reported a foreign exchange loss of 395 million yen and a foreign currency translation adjustment of 405 million yen due to exchange rate fluctuations, impacting its financial performance. Additionally, SanBio recognized deferred tax liabilities, leading to deferred income taxes of negative 446 million yen, affecting its earnings performance.

The most recent analyst rating on (JP:4592) stock is a Sell with a Yen1010.00 price target. To see the full list of analyst forecasts on SanBio Co stock, see the JP:4592 Stock Forecast page.

SanBio Reports Continued Financial Losses Amid Operational Challenges

SanBio Company Limited reported its consolidated financial results for the nine months ending October 31, 2025, showing a continued net loss with operating and ordinary income also in negative figures. The company’s financial position weakened compared to the previous period, with a significant decrease in total assets and net assets, reflecting ongoing challenges in its operations and market positioning.

The most recent analyst rating on (JP:4592) stock is a Sell with a Yen1010.00 price target. To see the full list of analyst forecasts on SanBio Co stock, see the JP:4592 Stock Forecast page.

SanBio Gains Approval for AKUUGO Marketing Changes

SanBio Co., Ltd. announced that the Ministry of Health, Labour and Welfare in Japan has approved a partial change to the marketing authorization for AKUUGO, a regenerative therapy for brain injuries. This change lifts certain shipment restrictions, allowing the company to proceed with its plans to launch the product following its NHI price listing. The company aims to expand its operations in the U.S. market with a Phase 3 clinical trial for traumatic brain injury and plans to discuss clinical trials for a stroke program in Japan, positioning itself as a leader in regenerative medicine.

The most recent analyst rating on (JP:4592) stock is a Sell with a Yen1010.00 price target. To see the full list of analyst forecasts on SanBio Co stock, see the JP:4592 Stock Forecast page.